The Revolution in Cholesterol Management: Putting PCSK9 Inhibitors into Practice

Monday, April 3, 2017
6:00 – 8:00 AM
Hyatt Regency Orlando- Regency Ballroom R 
This activity is supported by an educational grant from Amgen Inc.

Download Program Materials

 

CLICK "BEGIN" TO EVALUATE SESSIONS, CLAIM CME, AND PRINT A CERTIFICATE OF ATTENDANCE OR CERTIFICATE OF PARTICIPATION.

Target Audience

This continuing medical education activity should be of substantial interest to endocrinologists and endocrine fellows, cardiologists, and other healthcare professionals caring for patients with lipid disorders including familial hypercholesterolemia.

Learning Objectives

Upon completion of this educational activity, learners will be better able to:

  • Summarize the biology and genetic underpinnings of dyslipidemia as related to the LDL receptor and PCSK9
  • Explain the results of IMPROVE-IT and FOURIER
  • Assess the relative strengths and weaknesses of traditional (statins and ezetimibe) vs newer (PCSK9-I) cholesterol-lowering therapies to treat patients with familial hypercholesterolemia (FH)
  • Evaluate strategies to optimize patient tolerance of and compliance to statin and ezetimibe treatment in FH and Diabetes Mellitus Type 2 (DM2)
  • Incorporate PCSK9-I appropriately for further needed cholesterol lowering in high-risk patients

Additional Information

AttachmentSize
PDF icon ENDO 2017_Revolution in Cholesterol Mgmt_Book.pdf2.06 MB
Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Topic Area: 
Lipid Disorders and Fatty Liver Diseases
General Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Level 6 (Patient Health)
Activity summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credits™
  • 2.00 CME Certificate of Participation
Course opens: 
03/30/2017
Course expires: 
04/03/2018
Rating: 
0
Program Director
Eliot A. Brinton, MD 
Director, Atherometabolic Research
Utah Foundation for Biomedical Research
Salt Lake City, Utah
 
Faculty
Sergio Fazio, MD, PhD
The William and Sonja Connor 
Chair of Preventive Cardiology
Professor of Medicine and Physiology & Pharmacology
Director, Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health and Science University
Portland, OR
 
John R Guyton, MD
Professor of Medicine
Director, Duke Lipid Clinic
Duke University Medical Center
Durham, NC
 
Harold Edward Bays, MD, FTOS, FACC, FACE, FNLA
Medical Director / President
Louisville Metabolic and Atherosclerosis Research Center
Louisville KY
 

 

 

 

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
 
The faculty reported the following relevant financial relationship(s) during the content development process for this activity: 
Harold Edward Bays MD: Consultant, Amgen, Astra Zeneca, Merk & Co.; Investigator, Amarin, Amgen, Astra Zeneca, Merk & Co.; Speaker, Amarin, Amgen, Astra Zeneca, Merk & Co.
Eliot A. Brinton, MD: Consultant, Akcea, Amarin, Amgen, Aralez, Arisaph, AstraZeneca, Kastle, Kowa, Merck, PTS Diagnostics, Regeneron, Sanofi-Aventis; Speaker, Aegerion, Akcea, Alexion, Amarin, Amgen, Janssen, Kowa, Merck, Regeneron, Sanofi-Aventis; Contracted Research, Amarin, Kowa, PTS Diagnostics
Sergio Fazio, MD: Ad Hoc Consultant, Amarin, Amgen, Sanofi, Kowa, Merck & Co.
John R Guyton, MD: Principal Investigator, Amarin, Amgen, Regeneron, Sanofi; Investigator, Regeneron; Speaker, Amgen
 
The following SPC member who reviewed content for this activity reported relevant financial relationships: 
Zahid Ahmad, MD: Research Support, Regeneron, FH Foundation; Consultant, Regeneron; Speaker, Amgen, Genzyme, Sanofi
 
The following SPC member who reviewed content for this activity reported no relevant financial relationships: 
Connie Newman, MD
 
The following SPC Committee members reported financial relationships:
Andrew Ahmann, MD: Research Support, Dexcom, Lexicon, Medtronic, Novo Nordisk; Consultant, Dexcom, Novo Nordisk, Trividia Health
Giuseppe Barbesino, MD: Spouse, employee of Genzyme
John Carmichael, MD: Research Support, Novo Nordisk, Chiasma, Novartis, Pfizer, Strongbridge Biopharma; Speaker, Novartis; Advisory Board, Pfizer, Chiasma, Ionis Pharmaceuticals
Natalie Cusano, MD: Research Support, Shire; Speaker, Shire
Joan Han, MD: Research Support, Rhythm Pharmaceutical
Alan Kelly, MD: Speaker, Eli Lilly
Lisa Nachtigall, MD: Consultant, Ipsen, Novartis, Corcept; Grant Support/Investigator, Chiasma
Neda Rasouli, MD: Research Support, Novo Nordisk, Calibra, INTARCIA Therapeutics, GlaxoSmithKline, Bristol Meyer Squibb, AstraZeneca /Amylin, Ionis Pharmaceuticals, Boehringer Ingelheim
 
The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.
 
The following SPC members reported no relevant financial relationships: Amy Rothberg, MD
 
Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 2.00 AMA PRA Category 1 Credits™
  • 2.00 CME Certificate of Participation